This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: February 17th, 2010 - February 17th, 2011
Statement of Need
This activity was developed for oncology physicians, nurses, and pharmacists who wish to enhance their competence concerning the treatment of patients with multiple myeloma.
This activity was developed for physicians, nurses, and pharmacists.
At the completion of this activity participants should be able to:
- Identify patient characteristics that should be considered when determining front-line treatment in multiple myeloma (MM)
- Describe optimal therapeutic approaches for maximizing response while minimizing toxicities in patients with MM
- Review the integration of novel drug therapies with stem cell transplantation and other treatment options in the front-line setting in MM
Agenda - 1 hour
• Articles/Commentaries: 45 minutes
• Evaluation/Post-Test: 15 minutes
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this educational activity for a maximum of 1. AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1 contact hour.
Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-001-H01-P.
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakersâ€™ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner
|Amanda Glazar, PhD||Global||Nothing to disclose|
|Jackie Dawson, MSN||Global||Nothing to disclose|
|Kathryn Gada, MSN||MLI||Nothing to disclose|
|Dana Delibovi||COEXM||Nothing to disclose|
|Susan Berry||COEXM||Nothing to disclose|
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.
*Katherine Sanvidge Shah, PharmD, BCOP, has nothing to disclose.
*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.
Charise Gleason, MSN, ANP-BC, AOCNP, is a consultant for Merck and Millennium.
*Nicole Wilson, PharmD, BCOP, has nothing to disclose.
*Content will include non-FDA-approved uses.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.